投资者因指称未披露合规问题和误导性陈述而起诉Humacyte。 Investors sue Humacyte over alleged nondisclosure of compliance issues and misleading statements.

对Humacyte公司提起的集体诉讼诉讼声称,该公司没有披露其Durham、北卡罗来纳州设施合规情况、林业发展局审查拖延和关于其商业前景的误导性陈述方面的问题。 A class action lawsuit against Humacyte, Inc. alleges the company failed to disclose issues with its Durham, North Carolina facility's compliance, FDA review delays, and misleading statements about its business prospects. 遭受损失的投资者可以在2025年1月17日之前加入诉讼并申请成为主要原告。 Investors who suffered losses can join the lawsuit and apply to be lead plaintiff by January 17, 2025.